Tonix Pharmaceuticals shares are trading lower after the company reported the enrollment for its Phase 3 RECOVERY study of Tonmya was stopped due to 'inadequate separation from placebo at week-12 based on interim analysis results of the first 50% of enrolled participants'.
Benzinga Newsdesk